Bioactive small molecule development project - gamma 33P ATP kinase assay and nanobret kinase assay
Ended Purchase Order Awarded
- Contract number
- 140D0425P0049
- Awardee
-
Reaction Biology Corporation UEI LDBCLKM4WJH1
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $59,768
Award facts
- Opportunity
-
- Notice of Intent to Sole Source Special Notice · 140D0425Q0732 · Posted Aug 15, 2025
- Contract value 100% obligated
- $59,768.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Malvern, PA 19355, USA
- Legislative mandates
-
- Other statutory authority
Award details come from SAM.gov/FPDS.
About this award
The National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health, awarded a $59.8K firm fixed-price purchase order to Reaction Biology Corporation for bioactive small molecule development services. The contract, awarded on September 19, 2025, with an ultimate completion date of September 22, 2026, encompasses Gamma 33P ATP kinase assay and NanoBRET kinase assay services to be performed at the contractor's facility in Malvern, Pennsylvania. This procurement was structured as a sole-source award under 41 U.S.C. 1901 and FAR 13.106-1(b)(1), with no small business set-aside applied. The government justified the sole-source approach based on the requirement for data consistency and methodology continuity in an ongoing development project, necessitating the same specialized assay services previously provided by Reaction Biology Corporation to maintain comparable sample analysis throughout the project duration.
Reaction Biology Corporation, a contract research organization specializing in advanced biochemical and preclinical research services, has established itself as a key provider for NCATS-funded kinase and enzyme research initiatives. The company, registered as a self-certified small disadvantaged business, operates proprietary screening platforms such as Kinase HotSpot and Methyltransferase HotSpot that enable comprehensive enzymatic testing for potential therapeutic compounds. The firm's portfolio of federal contracts with NCATS and the National Institute on Drug Abuse demonstrates consistent technical capability in delivering complex scientific testing services, with prior awards ranging from $11K to $166.5K for similar kinase profiling, biochemical assays, and cellular screening projects supporting translational research across multiple therapeutic domains.
Quick answers
Who was awarded contract 140D0425P0049?
140D0425P0049 was awarded to Reaction Biology Corporation by Interior Business Center (Office of Policy Management and Budget) on September 19, 2025.
How much is contract 140D0425P0049 worth?
The government has obligated $59,768 on 140D0425P0049.
Which agency awarded contract 140D0425P0049?
Interior Business Center (Office of Policy Management and Budget) awarded 140D0425P0049, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 140D0425P0049 competed?
The extent of competition for 140D0425P0049 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award